Reviews/Perioperative Immunotherapy Solid Tumours/Neoadjuvant dual immune checkpoint inhibitor pathological complete response in microsatellite instability-high colon cancer
Msi Colon · PERIO-MSI-01 · v2
Borderline: within 4 points of the Established/Likely boundary, so a re-grade could land either side.
In colon cancer with a faulty DNA mismatch-repair system, giving two immune-checkpoint drugs before surgery shrinks or eliminates the tumour in a large share of patients: three cohorts of the NICHE programme and NICHE-3 each report that around two-thirds of patients had no residual tumour at surgery [18][5][4][19], and an independent real-world series saw a lower but still substantial rate [17]. This part of the claim is strong and repeated. The second part — that this could let patients keep their colon instead of having surgery — is much thinner. The patients in those dual-drug colon trials all went on to surgery, so they show tumour clearance, not organ preservation; the colon evidence for avoiding surgery comes from single-drug studies [21][24], and the only dual-drug organ-preservation reports are small rectal series [8][10]. The panel therefore accepted the high-response finding but treated the organ-preservation element as still emerging.
Multiple neoadjuvant dual-checkpoint cohorts in dMMR colon cancer report high pathological complete response: 68% in the 115-patient NICHE-2 [18], 69% (22/32) in the final NICHE analysis [5], 68% in the 59-patient NICHE-3 using nivolumab plus relatlimab [4], and 100% pathological response with 12 complete responses in the original 20-patient dMMR NICHE cohort [19]. An independent real-world AGEO cohort confirms direction at a lower 42% pCR, with one toxic death [17]. Non-operative management in colon is documented with monotherapy — tislelizumab [21] and single-cycle pembrolizumab [24] — while dual-checkpoint organ preservation appears only in small rectal material ([8] n=1; [10] n=5). A modeling study argues surgery-alone recurrence in dMMR colon is already very low [23]. The contested point: The division is between the pCR finding, which is consistent and replicated across the dual-ICI colon trials [18][5][4][19], and the organ-preservation rider, for which the colon evidence is monotherapy ([21][24]) or the dual-ICI evidence is rectal and tiny ([8][10]). Whether avoiding surgery adds net benefit is further disputed by [23], which notes stand-alone neoadjuvant immunotherapy without radical surgery is not investigated in colon cancer.
All 24 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Perioperative Immunotherapy Solid Tumours, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
Organ-preservation overreach: the pivotal dual-ICI COLON trials [18][19][5][4] all proceeded to surgery and demonstrate pCR, not preservation. Colon non-operative-management data is monotherapy ([21] tislelizumab, [24] pembrolizumab); dual-checkpoint organ preservation is shown only in rectal case material ([8] n=1, [10] n=5). The claim couples a well-supported pCR finding to a preservation inference the dual-ICI colon corpus does not yet carry.
pCR is a pathological surrogate; long-term disease-free and overall survival are immature (median follow-up 8-26 months across [18][4]), so durable organ-preservation outcomes are unproven.
Where it remains uncertain. The pivotal dual-ICI colon trials all proceeded to surgery [18][19][5][4]; colon non-operative management is shown only with monotherapy [21][24] and dual-ICI organ preservation only in small rectal series [8][10].
Aleatory
The independent cohort reached 42% pCR versus the high-60s% in trials [17][18], reflecting patient-level variability outside selected trial populations, plus a reported toxic death.
Epistemic
Disease-free and overall survival are not mature (median follow-up 8-26 months across [18][4]), so durable outcomes are unknown.
Inferential
The claim's organ-preservation value rests on inferring durable cancer control from a pathological surrogate [18][4] rather than measured long-term outcomes.
The load-bearing papers from a corpus of 24, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Independent dual-checkpoint regimen (nivo+relatlimab) in dMMR colon, pCR 68%, replicating magnitude.
“40 (68%; 95% CI: 54-79%) pathologic complete responses”
Panel auditInternal validity: medium · scope of inference: Locally advanced dMMR colon cancer, neoadjuvant nivolumab plus relatlimab.Key limitations: single-arm · short follow-up · dual checkpoint is PD-1 plus LAG-3, not CTLA-4
Confirms high pCR (69%) in the completed dMMR NICHE cohort.
Panel auditInternal validity: medium · scope of inference: Non-metastatic resectable dMMR colon cancer, neoadjuvant nivolumab plus ipilimumab.Key limitations: conference abstract · small dMMR cohort · validation ongoing per authors
Dual-ICI complete response enabling organ preservation — but rectal, single case.
“After neoadjuvant treatment with one dose of ipilimumab and two doses of nivolumab a complete clinical and pathological response was documented”
Panel auditInternal validity: low · scope of inference: One patient with locally advanced MSI-H/dMMR rectal cancer.Key limitations: rectal not colon · n=1 case report · no rate estimable
It argues recurrence is very low after surgery alone and the NNT for added immunotherapy benefit exceeds 20, cautioning against the organ-preservation/benefit premise despite acknowledging high pathological response.
Panel auditInternal validity: medium · scope of inference: Operable dMMR colon cancer, modelled outcomes of neoadjuvant immunotherapy added to surgery.Key limitations: modeling with assumptions · non-comparable cohorts · stand-alone organ preservation not actually investigated
4 of 24 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
The high-pCR component is near-Established and replicated, but surrogate endpoints, concentration in the NICHE platform, and dual-ICI organ-preservation evidence that is still only monotherapy or rectal hold the compound claim at Likely.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Dual-ICI colon trial with planned non-operative management. Every pivotal dual-ICI colon trial proceeded to surgery [18][19][5][4], so organ preservation with this regimen is inferred, not observed. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A prospective dual-checkpoint colon trial offering watch-and-wait to complete responders with protocolised surveillance and surgical salvage.
Open question: Does neoadjuvant dual-checkpoint blockade allow durable colon preservation without surgery in dMMR colon cancer? Why it is still open: All dual-ICI colon trials in the corpus proceeded to surgery [18][19][5][4]; colon non-operative data are monotherapy [21][24] and dual-ICI preservation is only rectal [8][10].
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19